Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Nevirapine Plus Zidovudine to Prevent Perinatal HIV in Thailand

This study has been completed.
Sponsor:
Collaborators:
Harvard School of Public Health
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Information provided by:
Institut de Recherche pour le Developpement
ClinicalTrials.gov Identifier:
NCT00398684
First received: November 13, 2006
Last updated: May 2, 2008
Last verified: May 2008

November 13, 2006
May 2, 2008
January 2001
Not Provided
Definitive HIV infection in infants as assessed by positive HIV DNA PCR on two peripheral blood samples
Same as current
Complete list of historical versions of study NCT00398684 on ClinicalTrials.gov Archive Site
Tolerance of nevirapine, in particular rashes.
Same as current
Not Provided
Not Provided
 
Nevirapine Plus Zidovudine to Prevent Perinatal HIV in Thailand
Not Provided

The purpose of this study was to assess the efficacy of a single dose of the drug nevirapine (NVP) given to pregnant women at onset of labor and to their infant 48-72 hours after birth in addition to standard oral zidovudine (ZDV or AZT) prophylaxis for the prevention of mother-to-child transmission of HIV-1.

Multicenter, randomized, three arms, double-blind, controlled study. Study population was HIV-infected pregnant women who were on ZDV prophylaxis for more than two weeks and gave informed consent. If eligible, women completed a baseline check-up. Women meeting selection criteria were randomly assigned to receive one of three study regimens, in addition to ZDV prophylaxis:

  1. One dose maternal NVP treatment at onset of labor, and one dose of infant NVP treatment 48-72 hours after birth
  2. One dose maternal NVP treatment at onset of labor, and one dose of infant placebo 48-72 hours after birth
  3. One dose maternal placebo at onset of labor, and one dose of infant placebo 48-72 hours after birth. This was the reference study arm.

Follow-up of women and infants was carried out on an outpatient basis except for delivery and the first three days after delivery.

AMENDMENT

After the first interim analysis, enrollment in Placebo-Placebo arm was terminated on May 2, 2002, according to the recommendation of the Data and Safety Monitoring Board. The target sample size was increased to 660, instead of 510, in each of the two remaining arms (N-N and N-P) to ensure enough power to test for non-inferiority between these arms with a limit of 2.5%.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
  • HIV Infections
  • Pregnancy
  • Drug: Single dose nevirapine to the mother and to the child
    One maternal 200 mg NVP dose at the onset of labor, and one dose of infant NVP (0.6 ml/6mg) between 48-72 hours after birth. [Infants less than 2,500g received only 0.2mL/kg]
  • Drug: Single dose nevirapine to the mother and placebo to the child
    One maternal 200 mg NVP dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. [Infants less than 2,500g received only 0.2mL/kg]
  • Drug: Single dose placebo to the mother and to the child
    One maternal placebo dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. [Infants less than 2,500g received only 0.2mL/kg]
  • Experimental: 1
    One dose maternal NVP treatment at onset of labor, and one dose of infant NVP treatment 48-72 hours after birth (NVP-NVP)
    Intervention: Drug: Single dose nevirapine to the mother and to the child
  • Experimental: 2
    One dose maternal NVP treatment at onset of labor, and one dose of infant placebo 48-72 hours after birth. (NVP-Placebo)
    Intervention: Drug: Single dose nevirapine to the mother and placebo to the child
  • Placebo Comparator: 3
    One dose maternal placebo at onset of labor, and one dose of infant placebo 48-72 hours after birth. This was the reference study arm. (Placebo-Placebo)
    Intervention: Drug: Single dose placebo to the mother and to the child

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1792
June 2004
Not Provided

Pre-Entry Criteria

Women were eligible for the study if they:

  • have evidence of HIV infection (documented by two HIV antibody tests on two different dates);
  • were to be provided ZDV Prophylaxis (starting at 28 weeks or as soon as possible thereafter);
  • intended to carry the pregnancy to term;
  • intended to deliver at and bring their infant to a study site for at least 12 months after delivery; and
  • could provide informed consent.

Inclusion criteria

Women are eligible for the study if they:

  • met all pre-entry criteria;
  • agreed not to breastfeed;
  • consented to participate and to be followed for the duration of the study;
  • presented the following laboratory values within 14 days prior to randomization:
  • hemoglobin > 8.0 mg/dl
  • absolute neutrophil count > 1000 cells/mm3
  • platelets > 100,000 cells/mm3
  • serum creatinine < 1.5 mg/dl (women with a serum creatinine > 1.5 mg/dl must have a measured eight-hour urine creatinine clearance > 70 ml/min)
  • SGPT less than 10 times the upper limit of normal NOTE: Women with a Grade 2 or Grade 3 SGPT value (between 2.6 and 10 times the upper limit of normal) were allowed on study; they were monitored monthly until delivery. If at any point their SGPT value rose to a Grade 4 (more than 10 times the upper limit of normal), they should not be dosed with the Study Drug.

Exclusion Criteria:

  • evidence of pre-existing fetal anomalies incompatible with life;
  • known hypersensitivity to any benzodiazepine or to NVP;
  • receipt of antiretroviral agent other than ZDV;
  • receipt of non-allowed concomitant treatment;
  • uncontrolled hypertension;
  • concurrent participation in another clinical trial;
  • women with a CD4 count <200/µL or history of oral candidiasis if they were not receiving PCP prophylaxis.
Female
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Thailand
 
NCT00398684
PHPT-2; R01-HD39615; ANRS 1208
Not Provided
Not Provided
Institut de Recherche pour le Developpement
  • Harvard School of Public Health
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Principal Investigator: Marc Lallemant, MD Institut de Recherche pour le Developpement
Institut de Recherche pour le Developpement
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP